GRAIL Inc (GRAL) Stock Surpasses Analyst Target Price of $105
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy GRAL?
Source: NASDAQ.COM
- Stock Performance: GRAIL Inc (Ticker: GRAL) has surpassed the average analyst 12-month target price of $105, currently trading at $106.02, indicating strong market confidence in the company's future prospects.
- Analyst Reactions: When a stock hits its target price, analysts may either downgrade their valuation or raise their target, reflecting the market's focus on fundamental changes at GRAIL Inc that could influence investor decisions.
- Target Price Distribution: Among analysts covered by Zacks, there is a range of target prices for GRAIL Inc, with the lowest at $100 and the highest at $110, and a standard deviation of $5, highlighting differing market perspectives on the company's future performance.
- Investor Signal: The stock's rise above the target price provides a strong signal for investors to reassess the company, prompting them to consider whether the current valuation is justified or if it might be time to take profits.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to fall
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 95.890
Low
38.00
Averages
60.86
High
83.71
Current: 95.890
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Super Bowl Ad Sparks Controversy Over Cancer Test
- Ad Controversy: The Super Bowl ad by Hims & Hers has sparked widespread debate over the reliability and ethical implications of its new cancer detection product, which claims to detect over 50 types of cancer before symptoms appear.
- Accuracy Concerns: Initial results indicate that the test only detects about 40% of cancers, meaning it may miss more than half of cases, potentially giving patients a false sense of reassurance about their health status.
- Mixed Market Response: Hims & Hers reported an EPS of 6 cents in its Q3 earnings, missing estimates, although its revenue of $598.97 million exceeded expectations; however, the company’s guidance for Q4 revenue fell below consensus, reflecting mixed performance.
- Pricing and Regulatory Challenges: The test is priced at $700, representing a 25% discount from the manufacturer's list price, but Grail has requested FDA approval under a stringent regulatory pathway, adding risks to its future market rollout.
See More
Hims & Hers Introduces New Cancer Test, But It Might Not Be Fully Prepared for Use.
Super Bowl Ad Controversy: Hims & Hers has released a new Super Bowl ad that is raising concerns among medical experts.
Promotion of Medical Products: The ad promotes the company's weight loss drugs, testosterone treatments, and a controversial early cancer detection test.
See More
Hims & Hers Launches Multi-Cancer Early Detection Test
- Product Launch: Hims & Hers Health has announced the launch of the Galleri multi-cancer early detection test developed by GRAIL, designed to identify over 50 types of cancer through blood testing before symptoms appear, although it may produce false positives and negatives.
- Pricing Strategy: The test is offered at a $250 discount for customers enrolled in the company's Labs plans, aiming to attract more users to participate in cancer screening and enhance the company's competitive position in the health tech sector.
- Market Demand Response: HIMS CEO Andrew Dudum emphasized that despite significant advancements in cancer screening technology, many diagnoses should have been made earlier, indicating a pressing market need for innovative detection tools that could drive future growth for the company.
- Strategic Implications: By launching the Galleri test, Hims & Hers not only showcases its innovative capabilities in telehealth but also has the potential to enhance customer loyalty by improving cancer screening rates, thereby creating long-term value for the company.
See More
GRAIL Submits FDA Application to Advance Early Cancer Detection
- FDA Submission: GRAIL has submitted the final module of its Galleri multi-cancer early detection test to the FDA, marking a pivotal milestone in the cancer screening landscape, which is expected to significantly improve the current state of cancer screening in the U.S.
- Clinical Trial Data: The submission is based on safety and performance results from the PATHFINDER 2 study involving 25,490 participants, demonstrating the effectiveness of the Galleri test in early cancer detection and potentially expanding opportunities for earlier treatment.
- NHS-Galleri Trial: This trial is the world's first prospective randomized controlled trial, recruiting over 140,000 asymptomatic participants to assess the Galleri test's impact on reducing late-stage cancers, highlighting its significant public health implications.
- Technological Innovation: GRAIL leverages next-generation sequencing and machine learning technologies to detect cancer at earlier stages through the Galleri test, aiming to reduce cancer mortality rates and improve patient outcomes.
See More
GRAIL Submits FDA Application to Advance Early Cancer Detection
- FDA Submission: GRAIL has submitted the final module of its Galleri multi-cancer early detection test to the FDA, marking a pivotal milestone in cancer screening that is expected to significantly enhance the effectiveness of cancer detection in the U.S.
- Clinical Trial Support: The submission is backed by results from the PATHFINDER 2 study involving 25,490 participants, demonstrating the safety and efficacy of the Galleri test, which could open new avenues for early treatment.
- NHS-Galleri Trial Scale: The NHS-Galleri trial recruited over 140,000 asymptomatic participants to assess the impact of the Galleri test on reducing late-stage cancers, highlighting its significant public health implications.
- Innovative Technology Potential: The Galleri test employs advanced genomic sequencing and machine learning technologies aimed at early detection of multiple deadly cancers, potentially reducing cancer mortality rates and improving patient survival outcomes.
See More
2025 IPO Class: 3 Stocks Showing Positive Chart Trends
- Initial Public Offerings (IPOs): IPOs provide investors with new insights into the market landscape.
- Investment Opportunities: They can also reveal previously overlooked investment opportunities.
See More
Hims & Hers Super Bowl Ad Sparks Controversy Over Cancer Test
- Ad Controversy: The Super Bowl ad by Hims & Hers has sparked widespread debate over the reliability and ethical implications of its new cancer detection product, which claims to detect over 50 types of cancer before symptoms appear.
- Accuracy Concerns: Initial results indicate that the test only detects about 40% of cancers, meaning it may miss more than half of cases, potentially giving patients a false sense of reassurance about their health status.
- Mixed Market Response: Hims & Hers reported an EPS of 6 cents in its Q3 earnings, missing estimates, although its revenue of $598.97 million exceeded expectations; however, the company’s guidance for Q4 revenue fell below consensus, reflecting mixed performance.
- Pricing and Regulatory Challenges: The test is priced at $700, representing a 25% discount from the manufacturer's list price, but Grail has requested FDA approval under a stringent regulatory pathway, adding risks to its future market rollout.
See More
Hims & Hers Introduces New Cancer Test, But It Might Not Be Fully Prepared for Use.
Super Bowl Ad Controversy: Hims & Hers has released a new Super Bowl ad that is raising concerns among medical experts.
Promotion of Medical Products: The ad promotes the company's weight loss drugs, testosterone treatments, and a controversial early cancer detection test.
See More
Hims & Hers Launches Multi-Cancer Early Detection Test
- Product Launch: Hims & Hers Health has announced the launch of the Galleri multi-cancer early detection test developed by GRAIL, designed to identify over 50 types of cancer through blood testing before symptoms appear, although it may produce false positives and negatives.
- Pricing Strategy: The test is offered at a $250 discount for customers enrolled in the company's Labs plans, aiming to attract more users to participate in cancer screening and enhance the company's competitive position in the health tech sector.
- Market Demand Response: HIMS CEO Andrew Dudum emphasized that despite significant advancements in cancer screening technology, many diagnoses should have been made earlier, indicating a pressing market need for innovative detection tools that could drive future growth for the company.
- Strategic Implications: By launching the Galleri test, Hims & Hers not only showcases its innovative capabilities in telehealth but also has the potential to enhance customer loyalty by improving cancer screening rates, thereby creating long-term value for the company.
See More
GRAIL Submits FDA Application to Advance Early Cancer Detection
- FDA Submission: GRAIL has submitted the final module of its Galleri multi-cancer early detection test to the FDA, marking a pivotal milestone in the cancer screening landscape, which is expected to significantly improve the current state of cancer screening in the U.S.
- Clinical Trial Data: The submission is based on safety and performance results from the PATHFINDER 2 study involving 25,490 participants, demonstrating the effectiveness of the Galleri test in early cancer detection and potentially expanding opportunities for earlier treatment.
- NHS-Galleri Trial: This trial is the world's first prospective randomized controlled trial, recruiting over 140,000 asymptomatic participants to assess the Galleri test's impact on reducing late-stage cancers, highlighting its significant public health implications.
- Technological Innovation: GRAIL leverages next-generation sequencing and machine learning technologies to detect cancer at earlier stages through the Galleri test, aiming to reduce cancer mortality rates and improve patient outcomes.
See More
GRAIL Submits FDA Application to Advance Early Cancer Detection
- FDA Submission: GRAIL has submitted the final module of its Galleri multi-cancer early detection test to the FDA, marking a pivotal milestone in cancer screening that is expected to significantly enhance the effectiveness of cancer detection in the U.S.
- Clinical Trial Support: The submission is backed by results from the PATHFINDER 2 study involving 25,490 participants, demonstrating the safety and efficacy of the Galleri test, which could open new avenues for early treatment.
- NHS-Galleri Trial Scale: The NHS-Galleri trial recruited over 140,000 asymptomatic participants to assess the impact of the Galleri test on reducing late-stage cancers, highlighting its significant public health implications.
- Innovative Technology Potential: The Galleri test employs advanced genomic sequencing and machine learning technologies aimed at early detection of multiple deadly cancers, potentially reducing cancer mortality rates and improving patient survival outcomes.
See More
2025 IPO Class: 3 Stocks Showing Positive Chart Trends
- Initial Public Offerings (IPOs): IPOs provide investors with new insights into the market landscape.
- Investment Opportunities: They can also reveal previously overlooked investment opportunities.
See More
